Catalog # |
Size |
Price |
|
|---|---|---|---|
| EK-071-05 | 96 wells | $610 |
| View/Download (PDF) - for reference only | |||||||||||||||||||||||||||||||||||||||||
|
| Suggested Procedure | ||||||||||||||||||||||||||||||||||||||||
|
| Recommended | ||||||||||||||||||||||||||||||||||||||||
 Data may differ slightly based on lot. | 0.06 ng/ml | ||||||||||||||||||||||||||||||||||||||||
|
Data may differ slightly based on lot. | 0.06 - 1.48 ng/ml | ||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
|
| <10% | ||||||||||||||||||||||||||||||||||||||||
|
| <15% | ||||||||||||||||||||||||||||||||||||||||
Urotensin-II level and its association with oxidative stress in early diabetic nephropathy.
Tabur S, Korkmaz H, Eren MA, O?uz E, Sabuncu T, Aksoy N. J Diabetes Complicat. 2015;29(1):115-9.
Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions.
Ulas T, Buyukhatipoglu H, Dal MS, et al. J Res Med Sci. 2013;18(3):205-9.
Urotensin II levels in patients with chronic kidney disease and kidney transplants.
Hursitoglu M, Tukek T, Cikrikcioglu MA, et al. Ups J Med Sci. 2012;117(1):22-7.
Is plasma urotensin II concentration an indicator of myocardial damage in patients with acute coronary syndrome?.
Babi?ska M, Holecki M, Prochaczek F, et al. Arch Med Sci. 2012;8(3):449-54.
Evaluation of various endothelial biomarkers in ankylosing spondylitis.
Taylan A, Sari I, Kozaci DL, et al. Clin Rheumatol. 2012;31(1):23-8.
Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.
Pehlivan Y, Onat AM, Comez G, Babacan T. Clin Rheumatol. 2011;30(6):837-42.
Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus.
Buyukhatipoglu H, Buyukaslan H, Pehlivan Y, et al. Int J Rheum Dis. 2011;14(3):276-81.
Plasma urotensin II as a marker for severity of rheumatic valve disease.
Ozer O, Davutoglu V, Ercan S, et al. Tohoku J Exp Med. 2009;218(1):57-62.
Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.
Suguro T, Watanabe T, Kodate S, et al. Clin Sci. 2008;115(11):327-34.
Possible pathogenic link between migraine and urotensin-II.
Bicak U, Karabiber H, Ozerol HI, Aslan M, Ilhan A, Yakinci C. J Child Neurol. 2008;23(11):1249-53.
Urotensin II and cardiomyopathy in end-stage renal disease.
Zoccali C, Mallamaci F, Benedetto FA, et al. Hypertension. 2008;51(2):326-33.
Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease.
Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C. Kidney Int. 2008;73(1):95-101.
Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension.
Suguro T, Watanabe T, Ban Y, et al. Am J Hypertens. 2007;20(2):211-7.
Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension.
Rdzanek A, Filipiak KJ, Karpi?ski G, Grabowski M, Opolski G. Int J Cardiol. 2006;110(2):175-8.
Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.
Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Am J Hypertens. 2006;19(5):505-10.
Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages.
Watanabe T, Suguro T, Kanome T, et al. Hypertension. 2005;46(4):738-44.
Social Network Confirmation